Pamela A. Norton

Pamela A. Norton

Auto-generated profile, based on publicly available information

Pamela A. Norton

Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1999 in Gastroenterology
Verified
Journal Article
Closed access
JZJianliang Zhu
Jianliang Zhu
Jian WuJian Wu
Jian Wu
EFEdward Frizell
Edward Frizell
SLShu-Ling Liu
Shu-Ling Liu
RBReza Bashey
Reza Bashey
MZMark A. Zern
Mark A. Zern

25 August 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMary Ann Comunale
Mary Ann Comunale
LRLucy Rodemich-Betesh
Lucy Rodemich-Betesh
JHJulie Hafner
Julie Hafner
MWMengjun Wang
Mengjun Wang
PNPamela Norton
Pamela Norton
AMAnand Mehta
Anand Mehta
We previously reported increased levels of protein-linked fucosylation with the development of liver cancer and identified many of the proteins containing the altered glycan structures. One such protein is alpha-1-antitrypsin (A1AT). To advance these studies, we performed N-linked glycan analysis on the five major isoforms of A1AT and completed a comprehensive study of the glycosylation of A1AT found in healthy controls, patients with hepatitis C- (HCV) induced liver cirrhosis, and in patients infected with HCV with a diagnosis of hepatocellular carcinoma (HCC). Patients with liver cirrhosis and liver cancer had increased levels of triantennary glycan-containing outer arm (α-1,3) fucosylation. Increases in core (α-1,6) fucosylation were observed only on A1AT from patients with cancer. We performed a lectin fluorophore-linked immunosorbent assay using Aleuria Aurantia lectin (AAL), specific for core and outer arm fucosylation in over 400 patients with liver disease. AAL-reactive A1AT was able to detect HCC with a sensitivity of 70% and a specificity of 86%, which was greater than that observed with the current marker of HCC, alpha-fetoprotein. Glycosylation analysis of the false positives was performed; results indicated that these patients had increases in outer arm fucosylation but not in core fucosylation, suggesting that core fucosylation is cancer specific. This report details the stepwise change in the glycosylation of A1AT with the progression from liver cirrhosis to cancer and identifies core fucosylation on A1AT as an HCC specific modification.

1 December 1987 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
PNP A Norton
P A Norton
RHR O Hynes
R O Hynes
To study the alternative splicing of fibronectin during embryogenesis and oncogenic transformation, we isolated cDNA clones of chicken fibronectin. The partial amino acid sequence deduced from sequencing of these clones showed that, overall, chicken fibronectin is approximately 80% identical with mammalian fibronectins. However, two of the three known regions of alternative splicing differed from this average. The V region was significantly more divergent, and RNA from embryonic chicken liver showed a pattern of V exon splicing which was distinct from that seen in human or rat fibronectins. In contrast, the EIIIB segment was very highly conserved (96%). As in mammals, this segment and another (EIIIA) were alternatively spliced in a cell-type-specific fashion. EIIIA+ and EIIIB+ species were almost absent in liver but predominated in total embryo RNA at all times from 2.5 to 11 days postfertilization. We also examined the possible contributions of fibronectin splicing and integrin receptor expression to the loss of fibronectin on oncogenic transformation. We detected little change in fibronectin splicing, other than a slight increase in representation of EIIIB+ species in fibroblasts after transformation by Rous sarcoma virus. It was also established that the overall reduction in fibronectin mRNA level observed after transformation was not accompanied by a decrease in integrin mRNA levels, indicating that fibronectin and integrin receptors are not coordinately regulated at the transcriptional level.

1 August 2008 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YSYing‐Hsiu Su
Ying‐Hsiu Su
MWMengjun Wang
Mengjun Wang
DBDean E. Brenner
Dean E. Brenner
PNPamela A. Norton
Pamela A. Norton
TBTimothy M. Block
Timothy M. Block

1 December 2007 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ADAnne Marie Dougherty
Anne Marie Dougherty
HGHaitao Guo
Haitao Guo
GWGael Westby
Gael Westby
YLYuanjie Liu
Yuanjie Liu
ESEnder Simsek
Ender Simsek
ACAndrea Cuconati
Andrea Cuconati
The high levels of hepatitis B virus (HBV) surface antigen (HBsAg)-bearing subviral particles in the serum of chronically infected individuals are thought to play a role in suppressing the HBV-specific immune response. Current therapeutics are not directed at reducing this viral antigenemia; thus, our group has focused on identifying inhibitors of HBsAg secretion. By using the HBV-expressing cell line HepG2.2.15, high-throughput screening of an 80,288-compound synthetic small-molecule library identified HBF-0259, an aromatically substituted tetrahydro-tetrazolo-(1, 5-a)-pyrimidine. Following resynthesis, HBF-0259 had a 50% effective concentration of approximately 1.5 μM in a secondary, HBV-expressing cell line, with a concentration that exhibited 50% cytotoxicity of >50 μM. The equilibrium concentration of HBF-0259 in aqueous solution at physiological pH was 15 to 16 μM; the selective index was thus >9. As intended by our screening paradigm, HBF-0259 is a selective, potent inhibitor of secretion of both subviral and DNA-containing viral particles, while the secretion of α-1-acid glycoprotein and α-1-antitrypsin was unaffected. The HBV e antigen, which is not a constituent of HBV particles, was also unaffected, suggesting that the secretion of particles bearing HBV structural glycoproteins is targeted directly. Inhibitory activity was also confirmed by transfection of HBsAg, indicating that the action of the compound is independent of those of other viral proteins. HBF-0259 had no effect on HBV DNA synthesis, demonstrating that inhibition is independent of viral genomic replication. Finally, HBF-0259 had little or no effect on the cell-to-cell spread of two unrelated viruses, suggesting that it is a specific inhibitor of secretion of HBsAg. Possible mechanisms of action and the implications for its development are discussed.

14 November 2007 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
PNPamela A. Norton
Pamela A. Norton
MCMary Ann Comunale
Mary Ann Comunale
JKJonathan Krakover
Jonathan Krakover
LRLucy Rodemich
Lucy Rodemich
NPNatalie Pirog
Natalie Pirog
TBTimothy M. Block
Timothy M. Block